Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

Authors

Mario Campone

Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France

Mario Campone , Aditya Bardia , Gary A. Ulaner , Sarat Chandarlapaty , Alice Gosselin , Séverine Doroumian , Vasiliki Pelekanou , Marina Celanovic , Hannah M. Linden

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.

First Author: Erika P. Hamilton

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

First Author: Sarat Chandarlapaty

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

First Author: Erika P. Hamilton

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.

First Author: Elgene Lim